Pretreatment patient demographic and disease characteristics
| Characteristic . | B-cell malignancies dose escalation (n = 25) . | T-cell malignancies dose escalation (n = 5) . | Hodgkin lymphoma expansion cohort (n = 4) . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 57 (23-92) | 68 (57-77) | 45 (22-79) |
| ≥65 | 8 (32) | 3 (60) | 1 (25) |
| Male sex | 16 (64) | 3 (60) | 1 (25) |
| ECOG performance status | |||
| 0 | 9 (36) | 0 (0) | 0 (0) |
| 1 | 16 (64) | 5 (100) | 4 (100) |
| Stage at study entry | |||
| I | 0 (0) | 1 (20) | 0 (0) |
| II | 0 (0) | 2 (40) | 0 (0) |
| III | 7 (28) | 1 (20) | 1 (25) |
| IV | 18 (72) | 1 (20) | 3 (75) |
| B-cell tumor type | |||
| Diffuse large B cell | 10 (40) | 0 (0) | 0 (0) |
| Follicular | 6 (24) | 0 (0) | 0 (0) |
| Other non-Hodgkin B cell | 2 (8) | 0 (0) | 0 (0) |
| Hodgkin | 7 (28) | 0 (0) | 4 (100) |
| T-cell tumor type | |||
| Peripheral T-cell lymphoma | 0 (0) | 2 (40) | 0 (0) |
| Cutaneous T-cell lymphoma | 0 (0) | 1 (20) | 0 (0) |
| Mycosis fungoides | 0 (0) | 2 (40) | 0 (0) |
| Time since diagnosis, median (range), y | 7.2 (1.4-17.3) | 6.6 (0.7-27.4) | 7.0 (1.8-11.1) |
| Prior treatments received | |||
| Check-point blockade (CTLA-4 or PD-1) | 0 (0) | 1 (20) | 3 (75) |
| Cytotoxic chemotherapy | 25 (100) | 5 (100) | 4 (100) |
| Autologous transplant | 11 (44) | 0 (0) | 3 (75) |
| Characteristic . | B-cell malignancies dose escalation (n = 25) . | T-cell malignancies dose escalation (n = 5) . | Hodgkin lymphoma expansion cohort (n = 4) . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 57 (23-92) | 68 (57-77) | 45 (22-79) |
| ≥65 | 8 (32) | 3 (60) | 1 (25) |
| Male sex | 16 (64) | 3 (60) | 1 (25) |
| ECOG performance status | |||
| 0 | 9 (36) | 0 (0) | 0 (0) |
| 1 | 16 (64) | 5 (100) | 4 (100) |
| Stage at study entry | |||
| I | 0 (0) | 1 (20) | 0 (0) |
| II | 0 (0) | 2 (40) | 0 (0) |
| III | 7 (28) | 1 (20) | 1 (25) |
| IV | 18 (72) | 1 (20) | 3 (75) |
| B-cell tumor type | |||
| Diffuse large B cell | 10 (40) | 0 (0) | 0 (0) |
| Follicular | 6 (24) | 0 (0) | 0 (0) |
| Other non-Hodgkin B cell | 2 (8) | 0 (0) | 0 (0) |
| Hodgkin | 7 (28) | 0 (0) | 4 (100) |
| T-cell tumor type | |||
| Peripheral T-cell lymphoma | 0 (0) | 2 (40) | 0 (0) |
| Cutaneous T-cell lymphoma | 0 (0) | 1 (20) | 0 (0) |
| Mycosis fungoides | 0 (0) | 2 (40) | 0 (0) |
| Time since diagnosis, median (range), y | 7.2 (1.4-17.3) | 6.6 (0.7-27.4) | 7.0 (1.8-11.1) |
| Prior treatments received | |||
| Check-point blockade (CTLA-4 or PD-1) | 0 (0) | 1 (20) | 3 (75) |
| Cytotoxic chemotherapy | 25 (100) | 5 (100) | 4 (100) |
| Autologous transplant | 11 (44) | 0 (0) | 3 (75) |
Data are presented as n (%) unless otherwise specified.
CTLA-4, cytotoxic T lymphocyte antigen-4; ECOG, Eastern Cooperative Oncology Group; PD-1, programmed cell death 1.